New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on September 5, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jennifer L Taubert, EVP of Worldwide Chair, Innovative Medicine at Johnson & Johnson, has recently sold 56,471 shares of the company’s stock. This significant transaction was valued at $10,040,543.
Recent Updates on JNJ stock
Johnson & Johnson (JNJ) experienced notable bearish trading activity with a significant volume of put options, particularly in the 175 and 180 strike prices, indicating a cautious market sentiment ahead of its earnings report expected on October 14th. The Put/Call Ratio stood at 1.88, reflecting a higher demand for puts over calls, and the implied volatility increased by over one point. Recent developments include claims linking Tylenol use in pregnancy to autism, a balanced outlook on its MedTech growth amidst competitive challenges, and positive trial results for its Varipulse platform and heart pump, which could influence future market perceptions.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson receives a solid overall score of 77.8, driven primarily by its strong financial performance and positive earnings call. The company’s robust margins, steady growth, and raised guidance indicate a positive outlook, while technical indicators suggest short-term caution due to potential overbought conditions. Valuation metrics further support the stock’s attractiveness, offering an appealing dividend yield.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 26.58%
Average Trading Volume: 8,357,175
Technical Sentiment Signal: Buy
Current Market Cap: $430.5B